Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
OtherArticle

Characterization of JNJ-2482272 [4-(4-methyl-2-(4-(trifluoromethyl)phenyl)thiazole-5-yl)pyrimidine-2-amine] as a Strong AhR Activator in Rat and Human

Kevin J. Coe, Mark Feinstein, J. William Higgins, Perry Leung, Brian P Scott, Judith Skaptason, Yuen Tam, Laurie P Volak, Jennifer Kinong, Anton Bittner, Heather McAllister, Nathan M Lim, Michael Hack and Tatiana Koudriakova
Drug Metabolism and Disposition June 9, 2022, DMD-AR-2021-000825; DOI: https://doi.org/10.1124/dmd.121.000825
Kevin J. Coe
1DMPK, Janssen Research & Development, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin J. Coe
  • For correspondence: kcoe2@its.jnj.com
Mark Feinstein
1DMPK, Janssen Research & Development, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. William Higgins
2Trestle Biotherapeutics, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Perry Leung
3Janssen Research & Development, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian P Scott
1DMPK, Janssen Research & Development, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Skaptason
4DMPK, Neurocrine Biosciences, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuen Tam
1DMPK, Janssen Research & Development, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurie P Volak
3Janssen Research & Development, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Kinong
5Pfizer, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anton Bittner
6Turnstone Biologics, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather McAllister
3Janssen Research & Development, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan M Lim
3Janssen Research & Development, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Hack
3Janssen Research & Development, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiana Koudriakova
1DMPK, Janssen Research & Development, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

JNJ-2482272, under investigation as an anti-inflammatory agent, was orally administered to rats q.d. at 60 mg/kg for six consecutive days. Despite high plasma exposure after single administration (Cmax of 7.1 µM), JNJ-2482272 had plasma concentration beneath the lower limit of quantification (3 ng/mL) after six consecutive days of dosing. To determine if JNJ-2482272 is an autoinducer in rats, plated rat hepatocytes were treated with JNJ-2482272 for two days. The major hydroxylated metabolites of JNJ-2482272 were isolated and characterized by MS and NMR analyses. Compared to the vehicle treated cells, a concentration-dependent increase was observed in the formation of Phase I and II-mediated metabolites coinciding with greater expression of P450s and UGTs in rat hepatocytes. CYP1A1, CYP1A2, CYP1B1, and UGT1A6 transcripts were predominantly induced, suggesting that JNJ-2482272 is an activator of the aryl hydrocarbon receptor (AhR). In a human AhR reporter assay, JNJ-2482272 demonstrated potent AhR activation with an EC50 value of 0.768 nM, a potency more comparable to the strong AhR activator and toxin 2,3,7,8-tetrachloro-dibenzodioxin (TCDD) than to weaker AhR activators 3-methylcholanthrene (3-MC), β-naphthoflavone (βNF), and omeprazole (OME). In plated human hepatocytes, JNJ-2482272 induced CYP1A1 gene expression with an EC50 of 20.4 nM and increased CYP1A activity > 50-fold from basal levels. In human recombinant P450s (rCYPs), JNJ-2482272 was exclusively metabolized by the CYP1 family of enzymes and most rapidly by CYP1A1. The summation of these in vitro findings bridges the in vivo conclusion that JNJ-2482272 is a strong autoinducer in rats and potentially in humans through potent AhR activation.

Significance Statement Drugs that induce their own metabolism (autoinducers) can pose challenges in drug development due to their lack of sustained exposures for pharmacology and safety assessment often precluding their development. JNJ-2482272 is demonstrated herein as a strong AhR activator and CYP1A autoinducer, explaining its near complete loss of exposure after repeat administration in rat, that is likely translatable to human (if progressed further) considering its nanomolar potency comparable to “classical” AhR ligands like TCDD despite bearing a “non-classical” drug structure.

  • aryl hydrocarbon receptors (AHR)
  • CYP induction
  • CYP1A
  • drug metabolism
  • nuclear receptors
  • Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 50 (6)
Drug Metabolism and Disposition
Vol. 50, Issue 6
1 Jun 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of JNJ-2482272 [4-(4-methyl-2-(4-(trifluoromethyl)phenyl)thiazole-5-yl)pyrimidine-2-amine] as a Strong AhR Activator in Rat and Human
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Metabolism and AhR Activation of JNJ-2482272

Kevin J. Coe, Mark Feinstein, J. William Higgins, Perry Leung, Brian P Scott, Judith Skaptason, Yuen Tam, Laurie P Volak, Jennifer Kinong, Anton Bittner, Heather McAllister, Nathan M Lim, Michael Hack and Tatiana Koudriakova
Drug Metabolism and Disposition June 9, 2022, DMD-AR-2021-000825; DOI: https://doi.org/10.1124/dmd.121.000825

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Metabolism and AhR Activation of JNJ-2482272

Kevin J. Coe, Mark Feinstein, J. William Higgins, Perry Leung, Brian P Scott, Judith Skaptason, Yuen Tam, Laurie P Volak, Jennifer Kinong, Anton Bittner, Heather McAllister, Nathan M Lim, Michael Hack and Tatiana Koudriakova
Drug Metabolism and Disposition June 9, 2022, DMD-AR-2021-000825; DOI: https://doi.org/10.1124/dmd.121.000825
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • P450 cell lines for xenobiotic metabolite generation
  • Human ADME properties of abrocitinib
  • Impact of physiological microenvironments on HepaRG cells
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics